Allstate
ALL
$210.99
-1.65%
The Allstate Corporation is one of the largest property and casualty insurers in the United States, primarily offering personal auto and homeowners insurance through a network of exclusive agents. It operates as a dominant, established player in the mature insurance sector, distinguished by its strong brand recognition and extensive distribution network. The current investor narrative centers on the company's recovery from prior underwriting challenges, with recent financials showing a significant rebound in profitability, and the ongoing debate focuses on its ability to sustain improved margins amid a competitive and potentially volatile claims environment.…
ALL
Allstate
$210.99
Related headlines
Investment Opinion: Should I buy ALL Today?
Rating: Hold. The core thesis is that Allstate presents a compelling but fully appreciated value story, where the market's deep discount to peers appropriately balances the spectacular but likely peak profitability against the company's strong financial health and defensive attributes.
Supporting evidence includes the extreme valuation discount (5.29x trailing P/E vs. industry low-teens), the robust balance sheet (Debt/Equity of 0.245, ROE of 33.6%), and the generation of substantial free cash flow ($9.88B TTM). However, these are counterbalanced by minimal revenue growth (1.52% YoY in Q4) and the high probability of earnings normalization from Q4's $3.83B net income peak, as implied by the higher forward P/E of 8.20x.
The thesis would upgrade to a Buy if the company demonstrates sustainability of Q4-level margins into 2026, proving the discount is unjustified, or if the stock price retreats meaningfully below $190, offering a larger margin of safety. It would downgrade to a Sell if quarterly net income falls below $2.0B, confirming margin reversion, or if the combined ratio deteriorates significantly. Relative to its history and the muted growth outlook, the stock is fairly valued at current levels, pricing in a cautious but not pessimistic earnings trajectory.
Sign up to view all
ALL 12-Month Price Forecast
Allstate is a high-quality, financially robust company trading at a deep value multiple, but the valuation likely correctly anticipates an earnings normalization. The stock offers defensive characteristics (beta 0.224) and shareholder-friendly cash flow, making it a stable Hold for value-oriented or income-focused portfolios, but not a compelling growth story. The stance would upgrade to Bullish on evidence of margin sustainability (e.g., two consecutive quarters of net income >$3B) or a price drop below $190 enhancing the margin of safety. It would turn Bearish if quarterly earnings collapse below $1.5B, signaling the recovery has fully reversed.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Allstate's 12-month outlook, with a consensus price target around $274.29 and implied upside of +30.0% versus the current price.
Average Target
$274.29
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$169 - $274
Analyst target range
Analyst coverage for Allstate is limited, with only 3 analysts providing estimates, indicating this large-cap stock may have less focused institutional research attention than peers. The average estimated EPS for the period is $25.26, with a range from $24.39 to $26.14, but a consensus price target and recommendation distribution are not provided in the data, making it impossible to calculate implied upside or characterize the overall sentiment. The available institutional ratings show a mixed but generally stable picture, with recent actions including an upgrade from 'Buy' to 'Hold' by TD Cowen in January 2026, while firms like Mizuho and Keefe, Bruyette & Woods maintain 'Outperform' ratings; the lack of a clear consensus target price and the minimal number of analysts covering the stock suggest higher uncertainty and potentially less efficient price discovery, which is unusual for a company of Allstate's size and may contribute to its observed low volatility.
Bulls vs Bears: ALL Investment Factors
The bull case, centered on a dramatic profitability recovery and deep valuation discount, currently holds stronger evidence, supported by concrete financial metrics like a 23.1% net margin and a 5.29x P/E. However, the bear case presents a compelling counter-argument focused on the sustainability of these peak margins in a cyclical industry. The single most important tension in the investment debate is whether the Q4 2025 margin surge represents a new, durable underwriting paradigm for Allstate or merely a cyclical peak that will normalize, compressing earnings and justifying the current low valuation multiple. The resolution of this tension will dictate the stock's direction more than any other factor.
Bullish
- Exceptional Profitability Recovery: Q4 2025 net income surged to $3.83B, yielding a net margin of 23.1%, a dramatic improvement from 3.7% in Q1 2025. Gross margin expanded to 52.96% from 30.1% a year ago, driven by successful pricing actions and lower catastrophic losses, signaling a strong operational turnaround.
- Extreme Valuation Discount: The stock trades at a trailing P/E of 5.29x and a forward P/E of 8.20x, a significant discount to typical P&C insurer multiples in the low-teens. This deep value gap suggests the market is pricing in a reversion of peak earnings, creating potential for multiple expansion if profitability proves sustainable.
- Robust Financial Health: The balance sheet is strong with a low debt-to-equity ratio of 0.245 and a stellar Return on Equity of 33.6%. The company generates substantial free cash flow ($9.88B TTM), providing ample liquidity for shareholder returns and strategic flexibility without financial strain.
- Low Market Correlation: With a beta of 0.224, ALL is approximately 78% less volatile than the broader market, offering a defensive characteristic. This low systematic risk makes it a potential portfolio stabilizer, especially during periods of market turbulence, as evidenced by its positive 3-month return (+1.57%) while the SPY fell -4.0%.
Bearish
- Unsustainable Peak Margins: The Q4 2025 gross margin of 52.96% and net margin of 23.1% are exceptionally high and likely driven by transient factors like favorable weather. Historical volatility in margins (e.g., 18.6% gross margin in Q1 2025) suggests a high risk of normalization, which the forward P/E of 8.20x (vs. trailing 5.29x) already anticipates.
- Stagnant Revenue Growth: Revenue growth is minimal, with Q4 2025 revenue of $16.59B representing only a 1.52% YoY increase. The top line has been flat, fluctuating between $16.2B-$17.1B over the past year, highlighting the challenges of growth in a mature, competitive P&C insurance market.
- Limited Analyst Coverage & Uncertainty: Only 3 analysts provide estimates for this large-cap stock, indicating lower institutional research attention and potentially less efficient price discovery. The lack of a consensus price target increases uncertainty for investors trying to gauge fair value and implied upside.
- Vulnerability to Catastrophic Events: As a major P&C insurer, profitability is highly sensitive to catastrophic loss activity. The recent margin expansion benefited from lower claims, but a return to normal or above-normal catastrophe years could swiftly reverse the earnings recovery, as seen in the company's volatile historical income.
ALL Technical Analysis
The stock is in a state of consolidation after a significant recovery, trading at $207.03, which is approximately 95% of its 52-week high of $216.75 and well above its 52-week low of $176.00. The 1-year price change of only +0.78% indicates a lack of clear directional trend over the longer term, with the stock currently positioned near the top of its range, suggesting it is testing resistance levels that could lead to either a breakout or a pullback. Recent momentum shows a short-term pullback, with the stock down -3.08% over the past month, which contrasts with its modest +1.57% gain over the past three months; this divergence from the positive 3-month trend signals a potential consolidation or profit-taking phase after the stock's earlier advance from its lows. Key technical support is anchored at the 52-week low of $176, while immediate resistance sits at the 52-week high of $216.75; a decisive breakout above resistance would signal a resumption of the uptrend, whereas a failure could see a retest of lower support levels. The stock exhibits low market correlation with a beta of 0.224, indicating it is approximately 78% less volatile than the broader market (SPY), which is typical for a large-cap insurer and suggests lower systematic risk for investors.
Beta
0.22
0.22x market volatility
Max Drawdown
-14.1%
Largest decline past year
52-Week Range
$185-$217
Price range past year
Annual Return
+10.6%
Cumulative gain past year
| Period | ALL Return | S&P 500 |
|---|---|---|
| 1m | +2.6% | +0.5% |
| 3m | -0.6% | -2.1% |
| 6m | +2.6% | +4.0% |
| 1y | +10.6% | +29.5% |
| ytd | +3.5% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALL Fundamental Analysis
Revenue growth has been modest but stable, with Q4 2025 revenue of $16.59 billion representing a 1.52% year-over-year increase; however, examining the quarterly sequence, revenue has fluctuated between $16.2-$17.1 billion over the past year, indicating a relatively flat top-line trajectory typical of a mature insurer. Profitability has improved dramatically, with Q4 2025 net income surging to $3.83 billion, yielding a robust net margin of 23.1%, and gross margin expanding significantly to 52.96% from 30.1% in the year-ago quarter; this margin expansion reflects successful pricing actions and lower catastrophic loss activity, marking a strong recovery from the weaker profitability seen in the first half of 2025. The balance sheet is healthy, with a strong Return on Equity of 33.6% and a conservative debt-to-equity ratio of 0.245; the company generates substantial cash flow, with trailing twelve-month free cash flow of $9.88 billion, providing ample liquidity for dividends, share buybacks, and organic growth without reliance on excessive external financing.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$9.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALL Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 5.29x, while the forward PE is 8.20x, based on estimated EPS of $25.26; the higher forward multiple suggests the market anticipates some normalization of earnings from the exceptionally strong Q4 2025 results. Compared to typical industry averages for P&C insurers (which often range in the low-teens), Allstate's trailing PE of 5.29x represents a significant discount, potentially reflecting market skepticism about the sustainability of its recent peak profitability or a view of the company as a value play within the financial sector. Historically, the stock's own trailing PE has ranged from deeply negative during loss-making periods in 2022-2023 to a recent high of 22.99x in Q1 2025; the current PE of 5.29x is near the lower end of its positive historical range, suggesting the market is pricing in conservative expectations despite the recent earnings surge, which could indicate a valuation gap if profitability proves durable.
PE
5.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1458x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
4.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks primarily stem from earnings volatility and margin sustainability. The company's net income swung from $595M in Q1 2025 to $3.83B in Q4 2025, demonstrating high sensitivity to claims activity and pricing cycles. While the debt-to-equity ratio of 0.245 is low, the core risk is a reversion of the Q4 gross margin of 52.96% towards its historical average, which would significantly compress the stellar 33.6% ROE. Revenue concentration in personal auto and homeowners insurance in North America also exposes the company to regional economic and regulatory shifts.
Market & Competitive Risks include valuation compression if the market continues to discount the sustainability of earnings. Trading at a trailing P/E of 5.29x versus typical industry multiples in the low-teens, the stock already prices in skepticism; however, a failure to maintain improved combined ratios could prevent any multiple expansion. The competitive P&C landscape pressures pricing power, limiting top-line growth potential. The stock's low beta of 0.224, while defensive, also means it may not participate fully in broad market rallies, as seen in its 0.78% 1-year return versus the SPY's 22.2% gain.
Worst-Case Scenario involves a severe hurricane or wildfire season coupled with a hard insurance market, leading to catastrophic losses that overwhelm recent pricing gains. This could trigger a rapid earnings decline, analyst downgrades, and a re-rating to a valuation reflecting permanent impairment. The realistic downside is anchored by the 52-week low of $176, which represents a -15% decline from the current price of $207.03. A drawdown to this level is plausible if Q4 2025 proves to be an earnings peak and subsequent quarters show significant normalization.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility: Profitability is highly sensitive to catastrophic events; Q4 2025's $3.83B net income could swiftly decline in a bad storm season. 2) Margin Reversion: The gross margin spike to 52.96% is unsustainable; normalization would compress ROE from its current 33.6%. 3) Growth Stagnation: Revenue growth is minimal (1.52% YoY), limiting upside potential in a mature market. 4) Analyst Uncertainty: Limited coverage (only 3 analysts) reduces visibility and consensus on fair value, potentially leading to erratic price moves on news.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $200-$220 as earnings normalize from recent peaks but remain solid, with the valuation discount providing support. The Bull Case (25% probability) targets $230-$250, requiring sustained high margins and a P/E re-rating. The Bear Case (15% probability) risks a drop to $176-$190 if catastrophic losses return and earnings collapse. The most likely outcome is the Base Case, where ALL remains a range-bound value stock, as the market waits for proof that its improved profitability is durable.
ALL appears significantly undervalued on a superficial basis, trading at a trailing P/E of 5.29x versus typical P&C insurer multiples in the low-teens. However, this discount reflects deep market skepticism about the sustainability of its Q4 2025 peak earnings (net margin of 23.1%). The forward P/E of 8.20x, based on estimated EPS of $25.26, indicates the market expects earnings to normalize. Therefore, the stock is likely fairly valued relative to its probable future earnings trajectory, not its recent past. The market is pricing in a reversion to mean profitability, not perpetual margin expansion.
ALL is a good buy for a specific investor profile: those seeking a defensive, value-oriented holding with strong cash generation and a significant discount to industry peers. With a trailing P/E of 5.29x and robust free cash flow, it offers a margin of safety. However, it is not a good buy for growth investors, as revenue is stagnant (+1.52% YoY), and the recent earnings surge is likely to normalize. The key risk is a reversion in profitability, which could lead to a -15% drawdown to its 52-week low of $176. A patient investor comfortable with cyclicality may find value here.
ALL is more suitable for a long-term (3+ year) investment horizon rather than short-term trading. Its low beta (0.224) and cyclical earnings profile mean short-term price movements may be muted or driven by unpredictable catastrophe losses, making timing difficult. For the long-term investor, the company's strong balance sheet (Debt/Equity 0.245), consistent free cash flow generation, and shareholder-friendly capital allocation support a buy-and-hold strategy focused on total return (dividends + buybacks + potential multiple expansion). The stock's value proposition is realized over full underwriting cycles, not quarterly earnings beats.